How Venture Philanthropy Helps Move Rare Disease Research Forward with Tim Brent
About this episode
Tim Brent discusses the role of venture philanthropy in advancing rare disease research and commercialization.
Getting discoveries out of the lab is only part of the commercialization journey. At some point, a promising idea reaches the stage where investment decisions can determine whether the science moves forward, stalls out, or becomes something that can truly reach patients. That moment is especially important in rare diseases, where the path to market can be long, complex, and difficult for traditional capital to support. My guest today is Tim Brent, Venture Principal with Pathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation. Tim brings experience across patient advocacy, specialty pharmaceutical operations, and venture investment, along with a personal family connection to rare disease communities. In his role, he sources and evaluates investment opportunities, supports diligence and transactions, and helps manage relationships with biotech companies after investment. We also discuss the practical side of the work, including how Tim finds opportunities, what makes a founder conversation stand out, and where promising science can start to lose momentum. He shares what patient input adds to diligence, why clear milestones and a strong…
Topics covered
- venture philanthropy
- rare diseases
- investment decisions
- biotech companies
- patient advocacy
More episodes of AUTM on the Air
- World Intellectual Property Report 2026: Technology on the Move with Intan M. Hamdan-Livramento and Julio D. Raffo
- Why Communication Matters in IP Strategy with Stephen Hall
- How Thermo Fisher Evaluates University Innovation with Hsiaoli Chen
- Royalty Stacks: Turning Tech Transfer Into a Strategy Game with Guru Venkatesan
Explore listener stats, chart rankings, contacts and more on the AUTM on the Air podcast page.